New Data Supports the Safety and Efficacy of Dupixent in Adults and Children with AD

The studies appear in in the Journal of the American Academy of Dermatology and American Journal of Clinical Dermatology.

Two new studies reinforce the efficacy and safety of Dupixent for the treatment of atopic dermatitis in children and adults.

In the Phase 3 LIBERTY AD pediatric trial data, nearly three times as many children achieved clear or almost clear skin when treated with Dupixent and topical steroids, and more than two-thirds experienced at least a 75 percent overall improvement of their disease compared to topical steroids alone at 16 weeks.  More than three times as many children experienced a significant reduction in itch with Dupixent compared to topical steroids alone, and improvements in itch and disease severity were observed with Dupixent as early as two weeks after the first dose and continued throughout active treatment.

The results also show that Dupixent significantly improved outcomes and quality of life, with no new safety signals.

These findings appear in the Journal of the American Academy of Dermatology (JAAD).

Results from the LIBERTY AD adult open-label extension 3-year trial extend the available data on the safety and sustained efficacy of Dupixent in adults with moderate-to-severe AD for up to 3 years, supporting its long-term continuous use with no lab monitoring needed. These results appear in American Journal of Clinical Dermatology.